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INTRODUCTION
Influenza vaccines inducing broad cross-reactive immune responses would be of 
great advantage for protection against both seasonal and emerging influenza 
viruses.DNA vaccines trigger both humoral and T-cell immunity which induce a broad 
and long-lived protectionIntradermal (i.d.) delivery of DNA vaccines has been the most effective way of 
immunisation using less antigen.New-generation DNA vaccines perform well, also in larger animals.
CONCLUSIONS
DNA vaccinated pigs were protected from infection or able to clear the virus 
infection more rapidly than the control group
The influenza DNA vaccine induced  broadly protective haemagglutination
inhibition (HI) and HA specific IgG antibodies able to cross-react with 
heterologous H1N1 and H3N2 viruses
Vaccine induced antibody levels were increased upon challenge with homologous 
and heterologous virus infections.
Protection against heterologous H1N1 challenge – Pilot study
DNA vaccine induces high antibody levels in pigs and protects against H1N1v-09 infection
Objectives/Study design
Objectives
Study 1 – Fig. 1A, B, Fig. 3:
•Pilot study, epidemal
 
delivery of DNA vaccine: comparison of gene gun (GG) and electroporation
 
(EP)
•Determine cross-protection from classical swine H1N1 infection by human H1N1v-09 DNA vaccine in swine.
Study design:
 
Influenza genes were codon-optimised and cloned in an expression vector. Four pigs were vaccinated twice, three weeks apart with either HA and NA genes from H1N1v-09 (A/California/7/09) 
alone or in combination with NP and M genes from the 1918 H1N1 virus, dorsal side of each ear and on inner side of each thigh. Each GG shot contained 2 μg
 
DNA, EP used 100 μg
 
DNA each i.d. injection. 
The pigs were challenged with A/swine/DK19126/93(H1N1) ten weeks
 
after last immunisation (Fig.3). One pig was included for each DNA vaccine group and four pigs were included in the un-vaccinated 
naïve group.
Study 2 – Fig. 2A, B, C, D, E, F, Fig. 4:
•Evaluate the protection from  H1N1v-infection in swine immunised with an H1N1v/H3N2 DNA vaccine based on the 2009 H1N1 pandemic HA and NA + 2007 H3N2 HA and NA + 1918 H1N1 pandemic NP 
and M genes.
Study design: Influenza genes were codon-optimised and cloned in an expression vector. Five pigs were vaccinated by EP (200 μg
 
total DNA in one injection, ~66.4 μg
 
HA DNA, each injection), twice, three 
weeks apart with HA and NA genes from H1N1v-09 and A/Wisconsin/67/05(H3N2) in combination with NP and M genes from the 1918 H1N1 virus, dorsal side of each ear and on inner
 
side of each thigh. The 
pigs were challenged with A/California/07/09(H1N1v) three weeks after last immunisation (Fig. 4). 
DNA vaccine induces high cross-reactive levels of HI and IgG antibodies in pigs
A) B)
A) B)
D)
C)
Fig. 3
Fig. 4
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Individual pigs, n=5 in each group
 Pigs vaccinated by DNA EP are either protected from infection or 
clear the virus infection more rapidly than un-vaccinated pigs. 
Sterile immunity observed for 2 of 5 DNA vaccinated pigs (Fig. 
2A).
 H1N1v-09 HI titre >40HAU at 7 days post 2.nd vaccination. 
Significant higher HI antibodies compared to un-vaccinated pigs 
(Fig. 2B)
The DNA vaccine induce high HA specific IgG antibodies after 
first vaccination which is increased after challenge (Fig. 2C)
 DNA vaccinated pigs clear the virus infection, heterologous to the 
vaccine component, more rapidly than unvaccinated pigs. Sterile 
immunity observed for the pig vaccinated with HA+NA by EP (Fig. 
1A). 
HI titre >40 at day 10 post 2.nd vaccination by EP. Higher levels of 
HI antibodies in DNA vaccinated pigs compared to non-vaccinated 
pigs (Fig.1B). 
Heterologous challenge trigger vaccine-generated H1N1v-09 HI 
antibodies. EP was chosen as the gene delivery method for the following study.
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Figure 1: DNA vaccine based on the HA+NA genes of H1N1v-09 virus, with or without the M + NP genes of H1N1 1918
Challenge: Classical swine H1N1 virus from 1993. (DNA vaccine groups n=1, Naïve group n=4)
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Antibodies against the H3N2 components in the DNA vaccine 
(included in the 2006 to 2008 protein vaccines) cross-reacted with 
the H3N2 components included in the 2009-10 protein vaccine 
(A/Brisbane/10/07) (Fig. 2D and E).
Cross-reactive H3N2 HI titre >40HAU at 21 days post 1.st 
vaccination (Fig. 2D)
The DNA vaccine based on the H1N1v HA and NA genes induce 
HA specific IgG antibodies that cross-react with the genetically and 
antigenetically different H1N1 virus from previous seasons 
(A/Brisbane/59/07). In addition, challenge by H1N1v induce an 
increase in antibodies against the seasonal H1N1 (Fig.2F)
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We have developed an influenza DNA vaccine expressing different influenza 
proteins of pandemic and seasonal origin and demonstrate protection in swine 
against infection with both heterologous
 
and homologous H1N1 virus infection.
The influenza DNA vaccine based on the surface glycoproteins
 
of pandemic 
H1N1v-09, seasonal H3N2 influenza viruses and internal proteins from the
 
 
pandemic 1918 H1N1 virus induced protection against homologous and
 
 
heterologous
 
virus infection in pigs.
Figure 2: DNA vaccine based on the HA+NA genes of H1N1v-09 +HA and NA of H3N2-05 + M + NP genes of H1N1 1918
Challenge: H1N1v-09 virus. (DNA vaccine group n=5, naïve group n=5)
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Figure 2: DNA vaccine based on the HA+NA genes of H1N1v-09 +HA and NA of H3N2-05 + M + NP genes of H1N1 1918
Challenge: H1N1v-09 virus. (DNA vaccine group n=5, naïve group n=5)
